Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin

Wu,Xia; Chen,Shangqing; Huang,Kechu; Lin,Gongping

doi:10.3892/mmr.2022.12904

Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin

Authors:
- Xia Wu
- Shangqing Chen
- Kechu Huang
- Gongping Lin
View Affiliations

Affiliations: Clinical Laboratory, Jin'an District Hospital, Fuzhou, Fujian 350011, P.R. China, Department of Blood Transfusion, Sanming Second Hospital, Yong'an, Fujian 366000, P.R. China, Department of Pediatric Surgery, Sanming First Hospital Affiliated to Fujian Medical University, Sanming, Fujian 365000, P.R. China, Department of Emergency, Jin'an District Hospital, Fuzhou, Fujian 350011, P.R. China
Published online on: November 30, 2022 https://doi.org/10.3892/mmr.2022.12904
Article Number: 17
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Doxorubicin (DOX) is an extensively used chemotherapeutic drug to treat leukemia. However, there remains a pivotal clinical problem of resistance to DOX in patients with leukemia. Erythroid 2‑related factor 2 (Nrf2) is a master regulator of antioxidation response which serves a critical role in maintaining cellular oxidative homeostasis. However, whether Nrf2 is involved in DOX resistance is not totally clear. It is well‑documented that triptolide, a widely used drug to treat autoimmune disorders, possesses anti‑cancer activities, yet whether triptolide affects leukemia cell sensitivity to DOX remains to be elucidated. The present study aimed to determine the role of triptolide‑mediated downregulation of Nrf2 in regulating leukemia cell ferroptosis and resistance to DOX. For this purpose, low‑dose DOX was used to establish DOX‑resistant K562 cells and HL‑60 cells. Nrf2 mRNA and protein expression were examined by quantitative PCR and western blotting assays. The effects of triptolide on leukemia cell viability, reactive oxygen species (ROS) levels, or lipid oxidation were determined by CCK8 assay, DCFH‑DA assay, or BODIPY 581/591 C11 assay, respectively. The results show that Nrf2 expression was significantly upregulated in DOX‑resistant leukemia cells and clinical leukemia samples. Silencing of Nrf2 significantly sensitized leukemia cells to DOX. Furthermore, it was demonstrated that triptolide inhibited Nrf2 expression and induced leukemia cell ferroptosis, as evidenced by increased ROS levels and lipid oxidation as well as decreased glutathione peroxidase 4 expression. Ectopic expression of Nrf2 significantly rescued triptolide‑induced leukemia cell ferroptosis. Notably, the present study showed that triptolide re‑sensitized DOX‑resistant leukemia cells to DOX. In conclusion, the present study indicated that Nrf2 served a critical role in leukemia cell resistance to DOX and triptolide‑induced ferroptosis and suggested a potential strategy of combination therapy using triptolide and DOX in leukemia treatment.

View Figures

View References

1	Du Y and Chen B: Detection approaches for multidrug resistance genes of leukemia. Drug Des Devel Ther. 11:1255–1261. 2017. View Article : Google Scholar : PubMed/NCBI
2	Yi Y, Gao L, Wu M, Ao J, Zhang C, Wang X, Lin M, Bergholz J, Zhang Y and Xiao ZJ: Metformin sensitizes leukemia cells to vincristine via activation of AMP-activated protein kinase. J Cancer. 8:2636–2642. 2017. View Article : Google Scholar : PubMed/NCBI
3	Brunning RD: Classification of acute leukemias. Semin Diagn Pathol. 20:142–153. 2003. View Article : Google Scholar : PubMed/NCBI
4	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
5	Burnett AK, Kell J and Rowntree C: Acute myeloid leukemia: Therapeutic indications. Curr Opin Hematol. 7:333–338. 2000. View Article : Google Scholar : PubMed/NCBI
6	Burnett A, Wetzler M and Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 29:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
7	Wang HW, Ma KL, Liu H and Zhou JY: Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen. Aging (Albany NY). 12:6018–6029. 2020. View Article : Google Scholar : PubMed/NCBI
8	Lothstein L, Israel M and Sweatman TW: Anthracycline drug targeting: Cytoplasmic versus nuclear-a fork in the road. Drug Resist Updat. 4:169–177. 2001. View Article : Google Scholar : PubMed/NCBI
9	Kruk I, Michalska T, Kładny J and Kubera-Nowakowska L: Luminescence investigations of redox cycling of adriamycin. Chemosphere. 44:83–90. 2001. View Article : Google Scholar : PubMed/NCBI
10	Davies GF, Roesler WJ, Juurlink BH and Harkness TA: Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma. 46:1199–1206. 2005. View Article : Google Scholar : PubMed/NCBI
11	Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M and Tsuruo T: Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood. 95:3214–3218. 2000. View Article : Google Scholar : PubMed/NCBI
12	Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T and Tsuruo T: Selective activation of apoptosis program by S-p-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin Cancer Res. 7:2513–2518. 2001.PubMed/NCBI
13	Xia CQ and Smith PG: Drug efflux transporters and multidrug resistance in acute leukemia: Therapeutic impact and novel approaches to mediation. Mol Pharmacol. 82:1008–1021. 2012. View Article : Google Scholar : PubMed/NCBI
14	Altucci L, Clarke N, Nebbioso A, Scognamiglio A and Gronemeyer H: Acute myeloid leukemia: Therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol. 37:1752–1762. 2005. View Article : Google Scholar : PubMed/NCBI
15	Waldmann T and Schneider R: Targeting histone modifications-epigenetics in cancer. Curr Opin Cell Biol. 25:184–189. 2013. View Article : Google Scholar : PubMed/NCBI
16	Liu T, Guo Q, Guo H, Hou S, Li J and Wang H: Quantitative analysis of histone H3 and H4 post-translational modifications in doxorubicin-resistant leukemia cells. Biomed Chromatogr. 30:638–644. 2016. View Article : Google Scholar : PubMed/NCBI
17	Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
18	Bebber CM, Müller F, Prieto Clemente L, Weber J and von Karstedt S: Ferroptosis in cancer cell biology. Cancers (Basel). 12:1642020. View Article : Google Scholar : PubMed/NCBI
19	Chen X, Kang R, Kroemer G and Tang D: Broadening horizons: The role of ferroptosis in cancer. Nat Rev Clin Oncol. 18:280–296. 2021. View Article : Google Scholar : PubMed/NCBI
20	Shi Z, Zhang L, Zheng J, Sun H and Shao C: Ferroptosis: Biochemistry and biology in cancers. Front Oncol. 11:5792862021. View Article : Google Scholar : PubMed/NCBI
21	Su Y, Zhao B, Zhou L, Zhang Z, Shen Y, Lv H, AlQudsy LHH and Shang P: Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Lett. 483:127–136. 2020. View Article : Google Scholar : PubMed/NCBI
22	Cai J, Yi M, Tan Y, Li X, Li G, Zeng Z, Xiong W and Xiang B: Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-II. J Exp Clin Cancer Res. 40:1902021. View Article : Google Scholar : PubMed/NCBI
23	Liu Q: Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol. 11:377–383. 2011. View Article : Google Scholar : PubMed/NCBI
24	Pigneux A, Mahon FX, Uhalde M, Jeanneteau M, Lacombe F, Milpied N, Reiffers J and Belloc F: Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp Hematol. 36:1648–1659. 2008. View Article : Google Scholar : PubMed/NCBI
25	Shao H, Ma J, Guo T and Hu R: Triptolide induces apoptosis of breast cancer cells via a mechanism associated with the Wnt/β-catenin signaling pathway. Exp Ther Med. 8:505–508. 2014. View Article : Google Scholar : PubMed/NCBI
26	Isharwal S, Modi S, Arora N, Uhlrich C III, Giri B, Barlass U, Soubra A, Chugh R, Dehm SM, Dudeja V, et al: Minnelide inhibits androgen dependent, castration resistant prostate cancer growth by decreasing expression of androgen receptor full length and splice variants. Prostate. 77:584–596. 2017. View Article : Google Scholar : PubMed/NCBI
27	Oliveira A, Beyer G, Chugh R, Skube SJ, Majumder K, Banerjee S, Sangwan V, Li L, Dawra R, Subramanian S, et al: Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F. Lab Invest. 95:648–659. 2015. View Article : Google Scholar : PubMed/NCBI
28	Philips BJ, Kumar A, Burki S, Ryan JP, Noda K and D'Cunha J: Triptolide-induced apoptosis in non-small cell lung cancer via a novel miR204-5p/Caveolin-1/Akt-mediated pathway. Oncotarget. 11:2793–2806. 2020. View Article : Google Scholar : PubMed/NCBI
29	Noel P, Von Hoff DD, Saluja AK, Velagapudi M, Borazanci E and Han H: Triptolide and its derivatives as cancer therapies. Trends Pharmacol Sci. 40:327–341. 2019. View Article : Google Scholar : PubMed/NCBI
30	Ni WJ and Leng XM: Down-regulated miR-495 can target programmed cell death 10 in ankylosing spondylitis. Mol Med. 26:502020. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Niu W, Xu L, Li J, Zhai Y, Sun Z, Shi W, Jiang Y, Ma C, Lin H, Guo Y and Liu Z: Polyphyllin II inhibits human bladder cancer migration and invasion by regulating EMT-associated factors and MMPs. Oncol Lett. 20:2928–2936. 2020. View Article : Google Scholar : PubMed/NCBI
33	Tang X, Li X, Zhang D and Han W: Astragaloside-IV alleviates high glucose-induced ferroptosis in retinal pigment epithelial cells by disrupting the expression of miR-138-5p/Sirt1/Nrf2. Bioengineered. 13:8240–8254. 2022. View Article : Google Scholar : PubMed/NCBI
34	Deshmukh P, Unni S, Krishnappa G and Padmanabhan B: The Keap1-Nrf2 pathway: Promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 9:41–56. 2017. View Article : Google Scholar : PubMed/NCBI
35	Zipper LM and Mulcahy RT: Erk activation is required for Nrf2 nuclear localization during pyrrolidine dithiocarbamate induction of glutamate cysteine ligase modulatory gene expression in HepG2 cells. Toxicol Sci. 73:124–134. 2003. View Article : Google Scholar : PubMed/NCBI
36	Ma CS, Lv QM, Zhang KR, Tang YB, Zhang YF, Shen Y, Lei HM and Zhu L: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells. Acta Pharmacol Sin. 42:613–623. 2021. View Article : Google Scholar : PubMed/NCBI
37	Kang Q and Yan S: Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells. Exp Ther Med. 9:1345–1350. 2015. View Article : Google Scholar : PubMed/NCBI
38	Asano T, Tsutsuda-Asano A and Fukunaga Y: Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of gamma-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells. Cancer Chemother Pharmacol. 64:715–721. 2009. View Article : Google Scholar : PubMed/NCBI
39	Nguyen T, Sherratt PJ, Huang HC, Yang CS and Pickett CB: Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem. 278:4536–4541. 2003. View Article : Google Scholar : PubMed/NCBI
40	DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI
41	Asensio-López MC, Soler F, Pascual-Figal D, Fernández-Belda F and Lax A: Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS One. 12:e01728032017. View Article : Google Scholar : PubMed/NCBI
42	Liu J, Mao W, Ding B and Liang CS: ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol. 295:H1956–H1965. 2008. View Article : Google Scholar : PubMed/NCBI
43	Nam LB, Choi WJ and Keum YS: Triptolide downregulates the expression of NRF2 target genes by increasing cytoplasmic localization of NRF2 in A549 cells. Front Pharmacol. 12:6801672021. View Article : Google Scholar : PubMed/NCBI
44	Yu D, Liu Y, Zhou Y, Ruiz-Rodado V, Larion M, Xu G and Yang C: Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proc Natl Acad Sci USA. 117:9964–9972. 2020. View Article : Google Scholar : PubMed/NCBI